Effects of Fatty Acid Therapy in Addition to Strong Statin on Coronary Plaques in Acute Coronary Syndrome: An Optical Coherence Tomography Study.
Acute Coronary Syndrome
/ diagnostic imaging
Aged
Docosahexaenoic Acids
/ therapeutic use
Drug Therapy, Combination
/ methods
Eicosapentaenoic Acid
/ therapeutic use
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ therapeutic use
Male
Middle Aged
Plaque, Atherosclerotic
/ diagnostic imaging
Prospective Studies
Rosuvastatin Calcium
/ therapeutic use
Tomography, Optical Coherence
fatty acid
fibrous cap
optical coherence tomography
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
18 08 2020
18 08 2020
Historique:
pubmed:
18
8
2020
medline:
10
3
2021
entrez:
18
8
2020
Statut:
ppublish
Résumé
BACKGROUND Vascular healing response associated with adjunctive n-3 polyunsaturated fatty acid therapy therapy in patients receiving strong statin therapy remains unclear. The aim of this study was to evaluate the effect of polyunsaturated fatty acid therapy with eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) in addition to strong statin therapy on coronary atherosclerotic plaques using optical coherence tomography. METHODS AND RESULTS This prospective multicenter randomized controlled trial included 130 patients with acute coronary syndrome treated with strong statins. They were assigned to either statin only (control group, n=42), statin+high-dose EPA (1800 mg/day) (EPA group, n=40), statin+EPA (930 mg/day)+DHA (750 mg/day) (EPA+DHA group, n=48). Optical coherence tomography was performed at baseline and at the 8-month follow-up. The target for optical coherence tomography analysis was a nonculprit lesion with a lipid plaque. Between baseline and the 8-month follow-up, fibrous cap thickness (FCT) significantly increased in all 3 groups. There were no significant differences in the percent change for minimum FCT between the EPA or EPA+DHA group and the control group. In patients with FCT <120 µm (median value), the percent change for minimum FCT was significantly higher in the EPA or EPA+DHA group compared with the control group. CONCLUSIONS EPA or EPA+DHA therapy in addition to strong statin therapy did not significantly increase FCT in nonculprit plaques compared with strong statin therapy alone, but significantly increased FCT in patients with thinner FCT. Registration URL: https://www.umin.ac.jp/ctr/; Unique identifier: UMIN 000012825.
Identifiants
pubmed: 32805184
doi: 10.1161/JAHA.119.015593
pmc: PMC7660823
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Docosahexaenoic Acids
25167-62-8
Rosuvastatin Calcium
83MVU38M7Q
Eicosapentaenoic Acid
AAN7QOV9EA
Banques de données
UMIN-CTR
['UMIN 000012825']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
e015593Références
N Engl J Med. 2005 Apr 7;352(14):1425-35
pubmed: 15755765
Coron Artery Dis. 2014 Jun;25(4):321-9
pubmed: 24769514
Arterioscler Thromb Vasc Biol. 2000 May;20(5):1262-75
pubmed: 10807742
Atherosclerosis. 2014 May;234(1):114-9
pubmed: 24637411
J Atheroscler Thromb. 2018 Sep 1;25(9):846-984
pubmed: 30135334
Cardiovasc Diabetol. 2014 Jan 13;13:13
pubmed: 24410834
N Engl J Med. 1997 Apr 10;336(15):1046-53
pubmed: 9091800
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Atherosclerosis. 2009 Feb;202(2):491-7
pubmed: 18572175
J Am Coll Cardiol. 2019 Jun 25;73(24):3168-3209
pubmed: 30423391
Circulation. 2001 Jun 26;103(25):3062-8
pubmed: 11425769
Circ Cardiovasc Imaging. 2012 Jul;5(4):433-40
pubmed: 22679059
Circ J. 2008 Oct;72(10):1631-9
pubmed: 18753698
J Atheroscler Thromb. 2015;22(1):52-61
pubmed: 25132379
Clin Cardiol. 2019 Jun;42(6):618-628
pubmed: 30993750
N Engl J Med. 1985 May 9;312(19):1205-9
pubmed: 3990713
J Am Coll Cardiol. 2004 Jun 2;43(11):2142-6
pubmed: 15172426
J Am Coll Cardiol. 2014 Dec 2;64(21):2207-17
pubmed: 25456755
J Lipid Res. 2006 Dec;47(12):2814-9
pubmed: 16983146
JAMA. 2004 Mar 3;291(9):1071-80
pubmed: 14996776
Mol Nutr Food Res. 2012 Jul;56(7):1073-80
pubmed: 22760980
J Atheroscler Thromb. 2013;20(7):603-15
pubmed: 23883545
J Am Coll Cardiol. 2012 Mar 20;59(12):1058-72
pubmed: 22421299
Atherosclerosis. 2008 Apr;197(2):524-33
pubmed: 17765904
Lancet. 2005 Oct 8;366(9493):1267-78
pubmed: 16214597
Circ J. 2016;80(2):450-60
pubmed: 26667367
Lancet. 2007 Mar 31;369(9567):1090-8
pubmed: 17398308
Circulation. 1994 Jan;89(1):36-44
pubmed: 8281670
Lancet. 1999 Aug 7;354(9177):447-55
pubmed: 10465168
Atherosclerosis. 2016 Nov;254:142-150
pubmed: 27744130
N Engl J Med. 2011 Jan 20;364(3):226-35
pubmed: 21247313
Am J Cardiol. 2019 May 15;123(10):1559-1564
pubmed: 30851939
Circulation. 2005 Mar 29;111(12):1551-5
pubmed: 15781733
N Engl J Med. 2019 Jan 3;380(1):11-22
pubmed: 30415628
J Cardiol. 2017 Dec;70(6):537-544
pubmed: 28863874
J Am Coll Cardiol. 2017 Feb 14;69(6):644-657
pubmed: 27989887
Lipids. 2002 Aug;37(8):789-96
pubmed: 12371750